All In Biotech

Drug Trial Radar · NCT04571437

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Letrozole With or Without Metronomic Capecitabine in First Line Treatment of Patients With ER-positive HER2 Negative Advanced Breast Cancer: A Randomized Phase II Study.

Last checked: Nov 19, 2026Latest source record: Oct 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

204

Planned (sponsor's estimate)

Start

Mar 1, 2020

Primary completion

Oct 31, 2021

Study completion Apr 30, 2022

Sponsor

Lead sponsor
Cairo UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.

Conditions

  • Breast Cancer
  • Estrogen Receptor-positive Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • CapecitabineDrug

    Capecitabine metronomic combined with Letrozole

  • Letrozole 2.5mgDrug

    Letrozole daily alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6 months Progression free survival rateTime frame: 6 months from the start of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Faculty of Medicine, Cairo University

    Cairo, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.